APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cell-Free Circulating Tumor DNA (ctDNA)

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Cell-Free Circulating Tumor DNA (ctDNA) Industry Growth and Trends Forecast to 2032

2 May 2026112 pages

Choose your research edition.

Industry ResearchCell-Free Circulating Tumor DNA (ctDNA) Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Cell-Free Circulating Tumor DNA (ctDNA) Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Cell-Free Circulating Tumor DNA (ctDNA) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cell-Free Circulating Tumor DNA (ctDNA) Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Cell-Free Circulating Tumor DNA (ctDNA) Market Analysis and Forecast 2026-2032227 pages · $4,950 USD

Market perspective

According to APO Research, the global Cell-Free Circulating Tumor DNA (ctDNA) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Cell-Free Circulating Tumor DNA (ctDNA) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Cell-Free Circulating Tumor DNA (ctDNA) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cell-Free Circulating Tumor DNA (ctDNA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Cell-Free Circulating Tumor DNA (ctDNA) market include Nexomics, Roche, ORIOMICS, Signatera, Illumina, Sysmex Corporation, Bio-Rad, Biocartis and QIAGEN, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Cell-Free Circulating Tumor DNA (ctDNA) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Cell-Free Circulating Tumor DNA (ctDNA) market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Cell-Free Circulating Tumor DNA (ctDNA) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Cell-Free Circulating Tumor DNA (ctDNA).

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Cell-Free Circulating Tumor DNA (ctDNA) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Cell-Free Circulating Tumor DNA (ctDNA) Market by Company

Nexomics

Roche

ORIOMICS

Signatera

Illumina

Sysmex Corporation

Bio-Rad

Biocartis

QIAGEN

GuardantHealth

GSK plc

AstraZeneca

NeoGenomics Laboratories

AmoyDx

Annoroad

Burning Rock Biotech

Cell-Free Circulating Tumor DNA (ctDNA) Segment by Type

Gastric Cancer Methylation Screening

Esophageal Cancer Methylation Screening

Colorectal Cancer Methylation Screening

Lung Cancer Methylation Screening

Liver Cancer Methylation Screening

Other Cancer Screening

Cell-Free Circulating Tumor DNA (ctDNA) Segment by Application

Hospital

Medical Center

Laboratory

Cell-Free Circulating Tumor DNA (ctDNA) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell-Free Circulating Tumor DNA (ctDNA) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cell-Free Circulating Tumor DNA (ctDNA) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell-Free Circulating Tumor DNA (ctDNA).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Cell-Free Circulating Tumor DNA (ctDNA) companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region (2021-2026) Table 4. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region (2027-2032) Table 6. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Share by Type (2021-2026) Table 9. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Share Forecasted by Type (2027-2032) Table 11. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Share by Application (2021-2026) Table 24. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Share Forecasted by Application (2027-2032) Table 26. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Cell-Free Circulating Tumor DNA (ctDNA) Industry Trends Table 37. Cell-Free Circulating Tumor DNA (ctDNA) Industry Drivers Table 38. Cell-Free Circulating Tumor DNA (ctDNA) Industry Opportunities and Challenges Table 39. Cell-Free Circulating Tumor DNA (ctDNA) Industry Restraints Table 40. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Company (2021-2026) Table 42. Global Cell-Free Circulating Tumor DNA (ctDNA) Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Cell-Free Circulating Tumor DNA (ctDNA) Key Company Headquarters & Area Served Table 44. Global Cell-Free Circulating Tumor DNA (ctDNA) Company, Product Type & Application Table 45. Global Cell-Free Circulating Tumor DNA (ctDNA) Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Cell-Free Circulating Tumor DNA (ctDNA) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Nexomics Company Information Table 49. Nexomics Business Overview Table 50. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 52. Nexomics Recent Development Table 53. Roche Company Information Table 54. Roche Business Overview Table 55. Roche Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 57. Roche Recent Development Table 58. ORIOMICS Company Information Table 59. ORIOMICS Business Overview Table 60. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 62. ORIOMICS Recent Development Table 63. Signatera Company Information Table 64. Signatera Business Overview Table 65. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 67. Signatera Recent Development Table 68. Illumina Company Information Table 69. Illumina Business Overview Table 70. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 72. Illumina Recent Development Table 73. Sysmex Corporation Company Information Table 74. Sysmex Corporation Business Overview Table 75. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 77. Sysmex Corporation Recent Development Table 78. Bio-Rad Company Information Table 79. Bio-Rad Business Overview Table 80. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 82. Bio-Rad Recent Development Table 83. Biocartis Company Information Table 84. Biocartis Business Overview Table 85. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 87. Biocartis Recent Development Table 88. QIAGEN Company Information Table 89. QIAGEN Business Overview Table 90. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 92. QIAGEN Recent Development Table 93. GuardantHealth Company Information Table 94. GuardantHealth Business Overview Table 95. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 97. GuardantHealth Recent Development Table 98. GSK plc Company Information Table 99. GSK plc Business Overview Table 100. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 102. GSK plc Recent Development Table 103. AstraZeneca Company Information Table 104. AstraZeneca Business Overview Table 105. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 107. AstraZeneca Recent Development Table 108. NeoGenomics Laboratories Company Information Table 109. NeoGenomics Laboratories Business Overview Table 110. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 112. NeoGenomics Laboratories Recent Development Table 113. AmoyDx Company Information Table 114. AmoyDx Business Overview Table 115. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 117. AmoyDx Recent Development Table 118. Annoroad Company Information Table 119. Annoroad Business Overview Table 120. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 122. Annoroad Recent Development Table 123. Burning Rock Biotech Company Information Table 124. Burning Rock Biotech Business Overview Table 125. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 127. Burning Rock Biotech Recent Development Table 128. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026) & (US$ Million) Table 130. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2021-2026) Table 131. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Share Forecast by Country (2027-2032) Table 133. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026) & (US$ Million) Table 135. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2021-2026) Table 136. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Share Forecast by Country (2027-2032) Table 138. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026) & (US$ Million) Table 140. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2021-2026) Table 141. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Share Forecast by Country (2027-2032) Table 143. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026) & (US$ Million) Table 145. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2021-2026) Table 146. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Share Forecast by Country (2027-2032) Table 148. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026) & (US$ Million) Table 150. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2021-2026) Table 151. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Share Forecast by Country (2027-2032) Table 153. Research Programs/Design for This Report Table 154. Authors List of This Report Table 155. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Cell-Free Circulating Tumor DNA (ctDNA) Product Image Figure 3. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 5. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region: 2025 VS 2032 Figure 6. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region (2021-2032) Figure 7. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Gastric Cancer Methylation Screening Image Figure 13. Global Gastric Cancer Methylation Screening Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Esophageal Cancer Methylation Screening Image Figure 15. Global Esophageal Cancer Methylation Screening Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Colorectal Cancer Methylation Screening Image Figure 17. Global Colorectal Cancer Methylation Screening Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Lung Cancer Methylation Screening Image Figure 19. Global Lung Cancer Methylation Screening Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Liver Cancer Methylation Screening Image Figure 21. Global Liver Cancer Methylation Screening Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Other Cancer Screening Image Figure 23. Global Other Cancer Screening Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Overview by Type (2021-2032) & (US$ Million) Figure 25. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Type 2025 VS 2032 Figure 26. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Share by Type (2021-2032) Figure 27. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Share by Type (2021-2032) Figure 28. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Share by Type (2021-2032) Figure 29. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Share by Type (2021-2032) Figure 30. Middle East and Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Share by Type (2021-2032) Figure 31. Hospital Image Figure 32. Global Hospital Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Medical Center Image Figure 34. Global Medical Center Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Laboratory Image Figure 36. Global Laboratory Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application 2025 VS 2032 Figure 39. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Share by Application (2021-2032) Figure 40. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Share by Application (2021-2032) Figure 41. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Share by Application (2021-2032) Figure 42. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Share by Application (2021-2032) Figure 43. Middle East and Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Share by Application (2021-2032) Figure 44. Global Top 5 and 10 Cell-Free Circulating Tumor DNA (ctDNA) Players Market Share by Revenue in 2025 Figure 45. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 46. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2021-2032) Figure 49. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2021-2032) Figure 52. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2021-2032) Figure 55. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2021-2032) Figure 58. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country: 2021 VS 2025 VS 2032 Figure 60. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2021-2032) Figure 61. Years Considered Figure 62. Research Process Figure 63. Key Executives Interviewed

Scope & coverage.

Types
  • Gastric Cancer Methylation Screening
  • Esophageal Cancer Methylation Screening
  • Colorectal Cancer Methylation Screening
  • Lung Cancer Methylation Screening
  • Liver Cancer Methylation Screening
  • Other Cancer Screening
Applications
  • Hospital
  • Medical Center
  • Laboratory
Companies covered
  • Nexomics
  • Roche
  • ORIOMICS
  • Signatera
  • Illumina
  • Sysmex Corporation
  • Bio-Rad
  • Biocartis
  • QIAGEN
  • GuardantHealth
  • GSK plc
  • AstraZeneca
  • NeoGenomics Laboratories
  • AmoyDx
  • Annoroad
  • Burning Rock Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2032)
  5. 1.4.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2026)
  6. 1.4.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2027-2032)
  7. 1.5 Key Regions Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032)
  8. 1.5.1 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (2021-2032)
2 Cell-Free Circulating Tumor DNA (ctDNA) Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Gastric Cancer Methylation Screening
  3. 2.1.2 Esophageal Cancer Methylation Screening
  4. 2.1.3 Colorectal Cancer Methylation Screening
  5. 2.1.4 Lung Cancer Methylation Screening
  6. 2.1.5 Liver Cancer Methylation Screening
  7. 2.1.6 Other Cancer Screening
  8. 2.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type
  9. 2.2.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Overview by Type (2021-2032)
  10. 2.2.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Historic Market Size Review by Type (2021-2026)
  11. 2.2.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecasted by Type (2027-2032)
  12. 2.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Regions
  13. 2.3.1 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Type (2021-2026)
  14. 2.3.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Type (2021-2026)
  15. 2.3.3 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Type (2021-2026)
  16. 2.3.4 South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Type (2021-2026)
  17. 2.3.5 Middle East and Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Type (2021-2026)
3 Cell-Free Circulating Tumor DNA (ctDNA) Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Hospital
  3. 3.1.2 Medical Center
  4. 3.1.3 Laboratory
  5. 3.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application
  6. 3.2.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Regions
  10. 3.3.1 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Cell-Free Circulating Tumor DNA (ctDNA) Industry Trends
  2. 4.2 Cell-Free Circulating Tumor DNA (ctDNA) Industry Drivers
  3. 4.3 Cell-Free Circulating Tumor DNA (ctDNA) Industry Opportunities and Challenges
  4. 4.4 Cell-Free Circulating Tumor DNA (ctDNA) Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Cell-Free Circulating Tumor DNA (ctDNA) Revenue (2021-2026)
  2. 5.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Key Company Headquarters & Area Served
  4. 5.4 Global Cell-Free Circulating Tumor DNA (ctDNA) Company, Product Type & Application
  5. 5.5 Global Cell-Free Circulating Tumor DNA (ctDNA) Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Cell-Free Circulating Tumor DNA (ctDNA) Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Cell-Free Circulating Tumor DNA (ctDNA) Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Nexomics
  2. 6.1.1 Nexomics Company Information
  3. 6.1.2 Nexomics Business Overview
  4. 6.1.3 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  6. 6.1.5 Nexomics Recent Developments
  7. 6.2 Roche
  8. 6.2.1 Roche Company Information
  9. 6.2.2 Roche Business Overview
  10. 6.2.3 Roche Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  12. 6.2.5 Roche Recent Developments
  13. 6.3 ORIOMICS
  14. 6.3.1 ORIOMICS Company Information
  15. 6.3.2 ORIOMICS Business Overview
  16. 6.3.3 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  18. 6.3.5 ORIOMICS Recent Developments
  19. 6.4 Signatera
  20. 6.4.1 Signatera Company Information
  21. 6.4.2 Signatera Business Overview
  22. 6.4.3 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  24. 6.4.5 Signatera Recent Developments
  25. 6.5 Illumina
  26. 6.5.1 Illumina Company Information
  27. 6.5.2 Illumina Business Overview
  28. 6.5.3 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  30. 6.5.5 Illumina Recent Developments
  31. 6.6 Sysmex Corporation
  32. 6.6.1 Sysmex Corporation Company Information
  33. 6.6.2 Sysmex Corporation Business Overview
  34. 6.6.3 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  36. 6.6.5 Sysmex Corporation Recent Developments
  37. 6.7 Bio-Rad
  38. 6.7.1 Bio-Rad Company Information
  39. 6.7.2 Bio-Rad Business Overview
  40. 6.7.3 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  42. 6.7.5 Bio-Rad Recent Developments
  43. 6.8 Biocartis
  44. 6.8.1 Biocartis Company Information
  45. 6.8.2 Biocartis Business Overview
  46. 6.8.3 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  48. 6.8.5 Biocartis Recent Developments
  49. 6.9 QIAGEN
  50. 6.9.1 QIAGEN Company Information
  51. 6.9.2 QIAGEN Business Overview
  52. 6.9.3 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  54. 6.9.5 QIAGEN Recent Developments
  55. 6.10 GuardantHealth
  56. 6.10.1 GuardantHealth Company Information
  57. 6.10.2 GuardantHealth Business Overview
  58. 6.10.3 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  60. 6.10.5 GuardantHealth Recent Developments
  61. 6.11 GSK plc
  62. 6.11.1 GSK plc Company Information
  63. 6.11.2 GSK plc Business Overview
  64. 6.11.3 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  66. 6.11.5 GSK plc Recent Developments
  67. 6.12 AstraZeneca
  68. 6.12.1 AstraZeneca Company Information
  69. 6.12.2 AstraZeneca Business Overview
  70. 6.12.3 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  72. 6.12.5 AstraZeneca Recent Developments
  73. 6.13 NeoGenomics Laboratories
  74. 6.13.1 NeoGenomics Laboratories Company Information
  75. 6.13.2 NeoGenomics Laboratories Business Overview
  76. 6.13.3 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  78. 6.13.5 NeoGenomics Laboratories Recent Developments
  79. 6.14 AmoyDx
  80. 6.14.1 AmoyDx Company Information
  81. 6.14.2 AmoyDx Business Overview
  82. 6.14.3 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  84. 6.14.5 AmoyDx Recent Developments
  85. 6.15 Annoroad
  86. 6.15.1 Annoroad Company Information
  87. 6.15.2 Annoroad Business Overview
  88. 6.15.3 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  90. 6.15.5 Annoroad Recent Developments
  91. 6.16 Burning Rock Biotech
  92. 6.16.1 Burning Rock Biotech Company Information
  93. 6.16.2 Burning Rock Biotech Business Overview
  94. 6.16.3 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  96. 6.16.5 Burning Rock Biotech Recent Developments
7 North America
  1. 7.1 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026)
  3. 7.3 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026)
  3. 8.3 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026)
  3. 10.3 South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst